INTRODUCTION {#h0.0}
============

Dengue virus (DENV) is the most significant arboviral infection of humans, with an estimated 390 million infections and 96 million symptomatic cases annually ([@B1]). The DENV complex consists of four distinct serotypes (DENV1 to -4). Infection with one serotype induces long-term protective immunity to the homologous serotype only. In fact, immunity to one serotype is associated with an increased risk of severe disease upon subsequent infection with a different serotype, a confounding factor for vaccine design. Many dengue vaccines in clinical trials are tetravalent live-attenuated virus formulations that are designed to simultaneously induce protective immunity to all 4 serotypes ([@B2][@B3][@B4]). However, in phase 3 efficacy trials in Asia and Latin America, the leading vaccine was 50 to 78% efficacious against serotypes 1, 3, and 4 but only 35 to 42% efficacious against serotype 2 ([@B5], [@B6]). Moreover, in vaccinees less than 5 years of age, incidence of hospitalization for virologically confirmed dengue was \~8-fold higher than that seen in matched nonvaccinated controls, demonstrating a critical need for new metrics of protective immunity ([@B7]). Here we describe the main site on DENV2 recognized by type-specific and durable neutralizing antibodies in people and other primates exposed to natural infections or a candidate live attenuated DENV2 vaccine.

The DENV envelope (E) glycoprotein is the main target of protective antibodies ([@B8]). The E protein is composed of three domains: I, II and III (designated EDI, EDII, and EDIII, respectively). Each DENV particle has 180 monomers of E that are organized into 90 dimers that cover the entire surface of the virus ([@B9]). The arrays of E proteins are arranged with icosahedral symmetry, with each asymmetric unit containing three E protein dimers. Some human monoclonal antibodies (hMAbs) that neutralize DENVs bind to quaternary structure epitopes that require assembly of E protein into homodimers or higher-order structures ([@B10][@B11][@B14]). Following infection or vaccination, it is a DENV-specific serum polyclonal antibody response that is responsible for protection. The principle targets of the human polyclonal antibody responses that neutralize DENVs have remained elusive.

We recently described hMAb 2D22, which is a DENV2-specific strongly neutralizing antibody isolated from a person exposed to a primary DENV2 infection ([@B10]). Our studies also demonstrated that 2D22 recognizes a complex quaternary epitope displayed on the intact virus but not recombinant E protein. A point mutation at amino acid position 323 in EDIII (residue highlighted in magenta in [Fig. 1A](#fig1){ref-type="fig"} and [B](#fig1){ref-type="fig"}) led to complete escape from 2D22 neutralization, indicating that the epitope includes EDIII residues ([@B10]). Recently Fibriansah et al. solved the structure of 2D22 bound to DENV2 and demonstrated that the antibody bound to a quaternary epitope that was formed by EDIII and EDII on two different monomers within a single dimer ([@B15]). While MAbs are powerful tools for epitope mapping, it is the polyclonal serum antibody response derived from long-lived plasma cells that is protective in people. Here we demonstrate that 2D22 defines a new class of quaternary epitopes that are the main targets of serum neutralizing antibodies in people exposed to DENV2 infections or a leading live attenuated DENV2 vaccine candidate.

![Design and characterization of rDENV4/2. (A) Amino acid alignment of DENV2 and DENV4 linear envelope domain III (EDIII) sequence, showing residues 296 to 395 of the entire E sequence (99 amino acids \[aa\] total). Residues differing between DENV2 and DENV4 are highlighted in yellow. Recombinant DENV4 virus containing EDIII from DENV2, designated rDENV4/2, replaces differing residues from DENV4 with those from DENV2, highlighted in green (40 aa total). A residue generated from the escape mutant is highlighted in magenta. (B) Crystal structure model of the DENV2 E protein dimer, with swapped residues colored in green and the DENV2 type-specific MAb 2D22 escape mutant residue highlighted in magenta. (C) Vero-81 or C6/36 cells were inoculated, viral supernatants were collected every 24 h, and the viral titer was subsequently determined on the respective cell type, or 1% of U937+DC-SIGN cells were infected, and the total percentage of infection was measured every 12 h (mean ± SD). (D) Immunoblotting of C3/36-grown viruses with anti-E and anti-PrM antibodies. The molecular mass of E is 55 kDa, and the molecular mass of prM is 21 kDa.](mbo0051524830001){#fig1}

RESULTS {#h1}
=======

Design of rDENV4/2 chimeric virus. {#s1.1}
----------------------------------

To further understand the role of EDIII in the epitope of 2D22 and DENV2 neutralizing antibodies in general, we designed and recovered a recombinant chimeric virus in which the entire DENV2 EDIII region was inserted into the backbone sequence of a DENV4 molecular clone to create a recombinant virus, designated rDENV4/2 (see [Fig. S1](#figS1){ref-type="supplementary-material"} and [S2](#figS2){ref-type="supplementary-material"} in the supplemental material). The recombinant virus, which had 40 amino acid changes in EDIII compared to the parental wild-type (wt) DENV4 strain ([Fig. 1A](#fig1){ref-type="fig"}; see [Table S1](#tabS1){ref-type="supplementary-material"} in the supplemental material), grew to similar levels as the wt viruses in C6/36 insect cells and in a human monocytic cell line (U937) expressing dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN), a known dengue receptor, but was partially growth impaired in Vero cells ([Fig. 1C](#fig1){ref-type="fig"}). DENVs are assembled inside cells as immature virions containing premembrane proteins (prM), which are cleaved in the Golgi apparatus, resulting in the formation of mature virions. Proteolytic cleavage of prM is inefficient, and the population of virions released from infected cells is an admixture displaying different stages of maturation. As the maturation state of DENVs may influence the display of some epitopes and sensitivity to antibody neutralization ([@B16][@B17][@B18]), immunoblots were performed to compare the maturation state of the rDENV4/2 chimera and the wt parental strains. From C6/36 cells, DENV2 particles had high levels of prM and DENV4 particles had low levels of prM relative to E protein, indicating that DENV4 virions were more mature ([Fig. 1D](#fig1){ref-type="fig"}). The rDENV4/2 chimera had a maturation state similar to that of DENV4, indicating that insertion of EDIII from serotype 2 minimally altered the maturation state of the backbone serotype 4 virus ([Fig. 1D](#fig1){ref-type="fig"}).

Monoclonal antibody binding and neutralization of rDENV4/2. {#s1.2}
-----------------------------------------------------------

To further evaluate the impact of EDIII exchange on overall E protein topology and virion structure, we probed the rDENV4/2 chimera with a panel of epitope-mapped human and mouse monoclonal antibodies (see [Table S2](#tabS2){ref-type="supplementary-material"} in the supplemental material). DENV cross-reactive MAbs 1C19, 1N5, and 1M7 bound to the chimera, indicating the preservation of cross-reactive epitopes ([Fig. 2A](#fig2){ref-type="fig"}) ([@B19]). DVC3.7 and DV4-E88 engage serotype-specific epitopes on EDIII of DENV2 and -4, respectively ([Fig. 2B](#fig2){ref-type="fig"} and [C](#fig2){ref-type="fig"}; see [Table S2](#tabS2){ref-type="supplementary-material"}) ([@B20], [@B21]). Consonant with recombinant virus design, DVC3.7 bound and neutralized the chimera, whereas DV4-E88 failed to bind or neutralize the chimera ([Fig. 2F](#fig2){ref-type="fig"} and [G](#fig2){ref-type="fig"}). Binding to and neutralization by 5H2, a nonhuman primate DENV4 serotype-specific MAb with an EDI epitope, is not disrupted in rDENV4/2, showing we have not affected neutralizing epitopes present on other domains ([Fig. 2D](#fig2){ref-type="fig"} and [H](#fig2){ref-type="fig"}; see [Table S2](#tabS2){ref-type="supplementary-material"}) ([@B22]). Overall, these results demonstrate that the rDENV4/2 chimera displays epitopes in a manner consistent with display on a properly folded and functional chimeric E protein. Transplantation of DENV2 EDIII into DENV4 also restored binding and neutralization by MAb 2D22, even though this antibody did not bind to DENV2 recombinant EDIII alone ([Fig. 2E](#fig2){ref-type="fig"} and [I](#fig2){ref-type="fig"}; see [Table S2](#tabS2){ref-type="supplementary-material"}). We predict that the full 2D22 epitope required for antibody binding and neutralization includes EDIII, as well as some conserved residues on adjacent domains, but that the residues on EDIII alone determine DENV2 specificity. Indeed, the cryo-electron microscopy structure of 2D22 bound to DENV2 demonstrates that the epitope consists of residues on EDIII and EDII of different monomers within a single dimer ([@B15]). As the fusion loop region of EDII is highly conserved across not only DENV but other flaviviruses as well, we predict it is the variability in EDIII that dictates 2D22 type-specificity. Of the eight contact residues identified in EDIII, only five differ between DENV2 and DENV4, suggesting these are critical residues important for 2D22 binding and neutralization ([@B15]).

![Recognition and neutralization of rDENV4/2 virus by DENV-specific monoclonal antibodies. Shown are the results from an ELISA capture assay with cross-reactive MAbs (A), DENV2-specific EDIII MAb DVC3.7 (B), DENV4-specific EDIII MAb DV4-E88 (C), DENV4-specific EDI MAb 5H2 (D), and DENV2-specific MAb 2D22 (mean ± SD) (E). A Vero-81 cell-based focus reduction neutralization test (FRNT) was performed using DENV2-specific EDIII MAb DVC3.7 (F), DENV4-specific EDIII MAb DV4-E88 (G), DENV4-specific EDI MAb 5H2 (H), or (I) DENV2-specific MAb 2D22 (I), and FRNT~50~ values (i.e., the concentration of antibody required to neutralize 50% of infection) were calculated (mean ± 95% confidence interval \[CI\]). §, FRNT~50~ of \>5 ng/µl.](mbo0051524830002){#fig2}

Polyclonal serum neutralization of rDENV4/2. {#s1.3}
--------------------------------------------

Natural primary DENV2 infections cause long-lived serotype-specific neutralizing antibody responses that can be detected for decades after exposure. To determine if "2D22-like" epitopes created by DENV2 EDIII transplantation into DENV4 were the main targets of these antibodies, neutralization assays were performed with well-characterized human and rhesus macaque dengue immune sera (see [Table S3](#tabS3){ref-type="supplementary-material"} in the supplemental material) and the rDENV4/2 and parental viruses. As expected, primary DENV2 immune sera strongly neutralized DENV2 but not DENV4 ([Fig. 3A](#fig3){ref-type="fig"}). Remarkably, in the majority of cases, these sera also efficiently neutralized the rDENV4/2 virus at levels similar to those measured with DENV2, indicating that EDIII replacement was sufficient to recreate the major DENV2 neutralizing epitopes recognized by these sera. The rDENV4/2 virus remained fully sensitive to neutralization by DENV4 immune sera ([Fig. 3B](#fig3){ref-type="fig"}). These data suggest that DENV2 and DENV4 type-specific neutralizing antibodies target different epitopes on the E protein, which are both preserved on the rDENV4/2 chimera. To determine if neutralization of rDENV4/2 is specific to DENV2 and DENV4 immune sera and not reflecting a global increase in sensitivity to neutralization by any dengue immune serum, a panel of primary DENV1 and DENV3 immune sera were tested against the same three viruses. The rDENV4/2 virus did not display increased sensitivity to neutralization by DENV1 or DENV3 immune sera (*P* \> 0.05 and *P* \> 0.05, respectively), demonstrating that the chimeric virus was not globally sensitive to antibody neutralization ([Fig. 3C](#fig3){ref-type="fig"} and [D](#fig3){ref-type="fig"}).

![rDENV4/2 neutralization by human and macaque DENV immune sera. A Vero-81 cell-based focus reduction neutralization test (FRNT) was performed using primary DENV2 (A), primary DENV4 (B), primary DENV1 (C), primary DENV3 (D), and monovalent DENV2 (E) vaccine immune sera, and FRNT~50~ values (i.e., the serum dilution factor required to neutralize 50% of infection) were calculated (mean ± 95% CI). Solid symbols indicate human sera, and open symbols indicate rhesus macaque sera. Sera that did not block 50% of infection at the lowest serum dilution factor were assigned a value of 10 (1/2 the lower limit of detection) for graphing and statistical analysis.](mbo0051524830003){#fig3}

DENV2 type-specific antibodies require complex epitope. {#s1.4}
-------------------------------------------------------

To determine if the DENV2 neutralizing epitope recognized by antibodies in immune sera was entirely contained within the transplanted EDIII or included residues on EDIII and adjacent domains, human immune sera were depleted of antibodies binding intact DENV2 virions or recombinant DENV2 EDIII ([Fig. 4A](#fig4){ref-type="fig"} and [B](#fig4){ref-type="fig"}) and then tested for their ability to neutralize the rDENV4/2 virus (see [Fig. S3](#figS3){ref-type="supplementary-material"} in the supplemental material). We have previously demonstrated that the recombinant DENV2 EDIII protein is properly folded and contains well-defined epitopes, such as the lateral ridge and A-strand epitopes recognized by some mouse and human neutralizing antibodies ([@B23], [@B24]). When six primary DENV2 human immune sera were depleted using DENV2 virions, between one-half to three-quarters (68% ± 21%) of the neutralizing potency was lost, depending on the serum sample ([Table 1](#tab1){ref-type="table"}). When the same sera were depleted using DENV2 rEDIII alone, five sera displayed minor loss in neutralization (22% ± 3%), and one sample (DT110) lost 58% of neutralization, a significantly smaller loss of neutralization than that of DENV2 depletions ([Table 1](#tab1){ref-type="table"}) (*P* \< 0.05). These results indicate that most DENV2 epitopes targeted by polyclonal type-specific human neutralizing antibodies require assembly of more higher-order structures than simple domains or monomers of E protein. We conclude that "2D22-like" EDIII-containing quaternary epitopes are a major target of serotype 2-specific long-lived polyclonal neutralizing antibodies that develop after DENV2 infections.

![Depletion of DENV2- and rEDIII-binding antibodies. (A) DENV2 immune sera were depleted using polystyrene beads coated with virus (DENV2 depleted) or BSA (BSA depleted), and removal of DENV2-binding antibodies was confirmed by ELISA, with wells directly coated with DENV2 antigen. (B) DENV2 immune sera were also depleted using Dynabeads coated with DENV2 rEDIII (rEDIII depleted) or BSA (BSA depleted), and removal of DENV2 rEDIII-binding antibodies was confirmed by ELISA with wells directly coated with rEDIII protein. DT001, IRB019, D031, DT110, DT134, and ss08/90 are sera from people exposed to natural DENV2 infections. 250.01.02, 250.01.05, and 250.01.19 are sera from people who received the NIH DENV2 vaccine. NHS, normal human serum.](mbo0051524830004){#fig4}

###### 

Neutralization of rDENV4/2 by human immune sera depleted of DENV2- or EDIII-binding antibodies[^a^](#ngtab1.1){ref-type="table-fn"}

  Serum                                          DENV2 virion depletion   DENV2 rEDIII depletion                               
  ---------------------------------------------- ------------------------ ------------------------ --------- ------- --------- ---------
  DENV2 infection sera                                                                                                         
      DT001                                      147                      82                       44        171     131       23
      IRB019                                     931                      261                      72        372     305       18
      DT031                                      1,288                    721                      44        1,493   1,140     24
      DT110                                      644                      76                       88        1,718   729       58
      DT134                                      235                      20                       91        168     129       23
      ss08/90                                    192                      64                       67        468     357       24
      Avg[^b^](#ngtab1.2){ref-type="table-fn"}                            68 ± 21                                    28 ± 15   
  DENV2 vaccine sera                                                                                                           
      250.01.02                                  148                      \<20                     100       136     228       0
      250.01.05                                  478                      37                       92        423     331       22
      250.01.19                                  318                      \<20                     100       272     \<20      100
      Avg                                                                                          97 ± 5                      41 ± 53
  All sera                                                                                                                     
      Avg[^b^](#ngtab1.2){ref-type="table-fn"}                                                     78 ± 22                     32 ± 29

A Vero-81 cell-based focus reduction neutralization test (FRNT) was performed on sera depleted of DENV2- or rEDIII-binding antibodies, and FRNT~50~ values (i.e., the serum dilution factor required to neutralize 50% of infection) were calculated as follows: % loss of neutralization = 100 − \[(DENV2 or rEDIII-depleted FRNT~50~/BSA-depleted FRNT~50~) × 100\].

There was a statistically significant difference between the percentage of loss of neutralization of DENV2 depleted and rEDIII depleted by two-tailed *t* test

To determine if dengue vaccines can induce "2D22-like" quaternary epitope-targeted neutralizing antibodies, we tested sera from 5 subjects who had developed DENV2 neutralizing antibodies after receiving a monovalent live attenuated DENV2 vaccine developed by the NIH ([@B25]). The vaccine sera neutralized DENV2 and the rDENV4/2 chimera but not DENV4, demonstrating that the vaccine induced neutralizing antibodies that tracked with the transplanted EDIII ([Fig. 3E](#fig3){ref-type="fig"}) (*P* \< 0.01). To determine if the vaccine-induced antibodies also recognized a quaternary epitope that extended beyond EDIII, three vaccine sera were depleted of antibodies binding intact DENV2 virions or recombinant DENV2 EDIII and then tested for the ability to neutralize the chimeric virus. In all three samples, depletion with whole virus led to a nearly complete loss of neutralizing antibodies ([Table 1](#tab1){ref-type="table"}). Removal of EDIII-specific antibodies resulted in a loss of neutralizing antibodies in one vaccine sample, while the other two samples retained the majority of neutralizing antibodies after EDIII depletion ([Table 1](#tab1){ref-type="table"}). Thus, the vaccine induced neutralizing antibodies that bind to epitopes contained within EDIII or more complex epitopes that extend beyond EDIII.

DISCUSSION {#h2}
==========

We have described an approach using whole-domain replacement to identify principal antigenic sites targeted by polyclonal antibodies following natural DENV infection or experimental live attenuated DENV vaccination. With the rDENV4/2 chimera, we observed a clear gain of DENV2 neutralization and no loss of sensitivity to neutralization by DENV4 sera, suggesting that the principal DENV4 neutralizing epitopes are distinct from DENV2 epitopes. Importantly, these data demonstrate that a single recombinant DENV can be designed that encodes major neutralizing epitopes from two virus serotypes.

Several recent studies point to the importance of quaternary epitopes as targets of human DENV neutralizing antibodies ([@B10][@B11][@B14]). DENV1 and 3 neutralizing hMAbs recognize distinct quaternary structure epitopes centered at the EDI/II hinge. However, only a small fraction (\<3%) of DENV-specific memory B-cell clones produce strongly neutralizing antibodies ([@B26]). It has not been clear if epitopes defined using human MAbs are the main targets of the polyclonal serum neutralizing antibody response as well. Our studies here demonstrate that the DENV2 serotype-specific epitopes targeted by a human MAb and polyclonal immune sera are closely related if not identical. The epitope is a complex quaternary epitope and includes critical residues in EDIII that determine serotype specificity.

The results reveal the fundamental importance of complex quaternary structures on the surface of DENV particles for driving potent antibody immune responses. Our results are entirely consistent with the 2D22 epitope structure reported by Fibriansah et al. in that the antibody footprint contains critical contact residues on EDIII of one monomer, as well as the fusion loop and BC loop of EDII on the adjacent monomer, bridging across the dimer ([@B15]). The structure also demonstrates that the 2D22 antibody contact sites on EDIII are not conserved between serotypes, but the contact sites on EDII are highly conserved between DENV2 and DENV4 ([@B15]). Thus, the serotype specificity of 2D22 is determined by EDIII, and transplantation of this domain into DENV4 was sufficient to create the complete functional epitope.

Dengue vaccines have been challenging to develop because of the need to formulate vaccines with four components that simultaneously induce durable neutralizing and protective antibodies to each serotype. As the current leading dengue tetravalent vaccine resulted in increased hospitalization in children under 9 years of age, there is an urgent need for refined metrics of epitope-specific neutralization responses. Without knowing the identity of critical epitopes and regions on viruses of the four serotypes targeted by neutralizing and protective polyclonal serum antibodies, it has been difficult to dissect tetravalent vaccine responses and efficacy data from ongoing clinical trials. Epitope-exchanged noroviruses have been used to decipher complex polyclonal response patterns in vaccine samples, and it is possible the same techniques can be used with dengue tetravalent vaccine sera ([@B27]). Our results demonstrate that the NIH monovalent live attenuated DENV2 vaccine induces neutralizing antibodies that are similar to those induced by natural infection. The rDENV4/2 chimera is a powerful tool for evaluating antibody site-specific responses following infection and vaccine trials. Recombinant DENVs expressing quaternary neutralizing antibody epitopes from 2 or more serotypes may lead to simpler and more effective vaccines than current tetravalent formulations.

MATERIALS AND METHODS {#h3}
=====================

Virus construction. {#s3.1}
-------------------

Recombinant viruses were constructed using a four-cDNA cloning strategy, the same strategy used to create wt DENV infectious clones (see [Fig. S1](#figS1){ref-type="supplementary-material"} in the supplemental material). Patterned after coronavirus cDNA clones ([@B28], [@B29]), the DENV-4 genome was subcloned into four separate cDNA plasmids. A T7 promoter was introduced into the 5′ end of the A fragment, and unique type IIS restriction endonuclease cleavage sites are introduced into the 5′ and 3′ ends of each fragment to allow for systematic assembly into a genome-length cDNA from which full-length transcripts can be derived ([@B28][@B29][@B30]).

The EDIII residues from DENV2 were introduced into the DENV4 A subclone by replacing E nucleotides 900 to 1179 with the corresponding nucleotides encoding variant DENV2 amino acids. The new A fragment with nucleotides from DENV2 was synthesized and inserted into the pUC-57 plasmid (BioBasic). The new A plasmid and the DENV4 B, C, and D plasmids were grown in *Escherichia coli* cells, purified, digested with the corresponding type IIS restriction enzymes, and ligated using T4 DNA ligase to create a full-length cDNA dengue viral genome. The full-length cDNA was transcribed into genome-length RNAs using T7 polymerase, as previously described by our group ([@B28][@B29][@B30]). Recombinant RNA was electroporated into BHK-21 cells, and cell culture supernatant containing viable virus was harvested. Virus was then passaged two times on C6/36 cells, centrifuged to remove cellular debris, and stored at −80°C. Passage 3 represents our working stock.

Cells. {#s3.2}
------

Mosquito *Aedes albopictus* C6/36 cells were grown in Gibco minimal essential medium (MEM) at 32°C. Vero-81 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) and DC-SIGN-expressing U937 cells (U937+DC-SIGN cells) were maintained in RPMI at 37°C. Medium was supplemented with fetal bovine serum (FBS) (10% for Vero-81 and 5% for C6/36 and U937+DC-SIGN cells), which was lowered to 2% after infection. The C6/36 and U937+DC-SIGN media were supplemented with nonessential amino acids, and U937+DC-SIGN medium was also supplemented with [l]{.smallcaps}-glutamine and 2-mercaptoethanol. All media were additionally supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin. All cells were incubated in 5% CO~2~ as previously described by our group ([@B30]).

DENV type-specific PCR and RFLP analysis. {#s3.3}
-----------------------------------------

Total RNA was isolated from viral supernatants and used as the template for cDNA synthesis using standard molecular techniques. Serotype-specific PCR and restriction fragment length polymorphism (RFLP) restriction endonuclease analyses were performed on cDNA samples in order to validate the purity of the recombinant viral preparations (see [Fig. S2A](#figS2){ref-type="supplementary-material"}, [B](#figS2){ref-type="supplementary-material"}, and [C](#figS2){ref-type="supplementary-material"} in the supplemental material).

Binding ELISA. {#s3.4}
--------------

Equal quantities of virus (as previously titrated by enzyme-linked immunosorbent assay \[ELISA\]) were captured using either mouse anti-DENV MAbs 4G2 and 2H2 or human MAb 1C19. Primary antibodies were diluted 4-fold starting at concentrations ranging from 10 ng/µl to 100 ng/µl. Alkaline phosphatase-conjugated secondary antibodies were used to detect binding of primary antibodies with *p*-nitrophenyl phosphate substrate, and reaction color changes were quantified by spectrophotometry, as previously described ([@B20]).

DENV immune sera. {#s3.5}
-----------------

Deidentified human DENV immune sera were collected from individuals with confirmed previous natural DENV infections (see [Table S2](#tabS2){ref-type="supplementary-material"} in the supplemental material). All donations were collected in compliance with the Institutional Review Board of the University of North Carolina at Chapel Hill (protocol 08-0895). Deidentified human immune sera previously collected from adults given the NIH monovalent DENV2 vaccine (ClinicalTrials.gov identifier NCT00920517) was provided by Anna Durbin and Stephen Whitehead. All sera were collected following informed consent and approval by the Western Institutional Review Board. Nonhuman primate immune sera were collected following experimental DENV infection and kindly provided by Carlos Sariol (see [Table S2](#tabS2){ref-type="supplementary-material"}) ([@B31]). All procedures were reviewed and approved by the Institute's Animal Care and Use Committee at Medical Sciences Campus, University of Puerto Rico (IACUC-UPR-MSC) and performed in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) (Animal Welfare Assurance no. A3421; protocol no. 7890108, 7890208, 7890209, and 7890210).

Virus titration and FRNT. {#s3.6}
-------------------------

One day prior to inoculation, 24-well cell culture plates were seeded with either 5 × 10^4^ Vero-81 cells or 1 × 10^5^ C6/36 cells. Prior to inoculation, growth medium was removed. Virus titrations were performed by serially diluting virus stocks 10-fold and then incubating them for 1 h at 37°C. After incubation, virus dilutions were added to cells for 1 h at 37°C and then overlaid with 1 ml 1% methylcellulose in OptiMEM I (Gibco) supplemented with 2% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin. After 3 to 6 days of incubation at 37°C, the overlay was removed, and cells were washed with phosphate-buffered saline (PBS) and fixed in 80% methanol. Plates were blocked with 5% instant milk made in PBS and then incubated with anti-E MAb 4G2 and anti-prM MAb 2H2, both diluted 1:500 in blocking buffer. The plates then were washed and incubated with horseradish peroxidase (HRP)-conjugated goat anti-mouse antibody (Sigma), diluted 1:2,500 in blocking buffer. Plates were washed, foci were developed with TrueBlue HRP substrate (KPL), and then foci were counted.

For the focus reduction neutralization test (FRNT), either MAbs or sera were diluted 4-fold and mixed with \~40 focus-forming units (FFU) of virus and then incubated for 1 h at 37°C. After incubation, virus and MAb or serum dilutions were added to cells for 1 h at 37°C, and then the overlay was added and processed as described above.

Growth curves. {#s3.7}
--------------

Either Vero or C6/36 cells were inoculated at a multiplicity of infection (MOI) of 0.01. Every 24 h, culture supernatant was harvested and centrifuged to remove cellular debris. Samples were frozen at −80°C until use. Fresh medium was replaced each day. Virus titers were determined on their propagating cell type, as described above. U937+DC-SIGN cells were infected at an initial infection of 1%, and every 12 h, a sample of cells was harvested, fixed, permeabilized, and probed with 2H2 (anti-prM antibody) conjugated to Alexa Fluor 488. Infected cells were quantified using a Guava flow cytometer (Millipore).

Immunoblotting. {#s3.8}
---------------

Virus stocks were diluted in PBS, mixed with 4× Laemmli sample buffer (Bio-Rad), and heated for 10 min at 50°C. Samples were run on 12% Protean TGX gels (Bio-Rad), transferred to polyvinylidene difluoride (PVDF) membrane, and blocked in 5% instant milk in PBS plus 0.05% Tween overnight at 4°C. Membranes were probed with 0.5 µg/ml anti-E MAb 4G2, 0.5 µg/ml anti-prM MAb 2H12, and MAb 5L20 in blocking buffer for 2 h at 37°C. After washing, HRP-conjugated anti-mouse or anti-human secondary antibodies were diluted 1:10,000 in blocking buffer and incubated for 1 h at room temperature. Membrane was exposed to chemiluminescent substrate and developed on film.

Depletion of DENV2-specific antibodies from immune sera. {#s3.9}
--------------------------------------------------------

Polyclonal immune sera were depleted of DENV2-binding antibodies as previously described ([@B10]). Briefly, polystyrene microspheres (Polysciences catalog no. 17135) were coated with purified DENV2 antigen (Microbix catalog no. EL-22-02-001) or the bovine serum albumin (BSA) control. Immune sera were depleted of antibodies by incubation with coated beads for 45 min at 37°C for at least three rounds, until maximum depletion of antibodies was measured. Depletions of antibodies were confirmed by ELISA.

Depletion of rEDIII-specific antibodies from immune sera. {#s3.10}
---------------------------------------------------------

Polyclonal immune sera were depleted of rEDIII-binding antibodies as previously described for rE-binding antibodies ([@B10]). Briefly, Dynabeads (Life Technologies catalog no. 14302D) were covalently conjugated to DENV2 rEDIII protein following the manufacturer's protocol or BSA control. Immune sera were depleted of antibodies by incubation with conjugated beads for 45 min at 37°C for at least three rounds, until maximum depletion of antibodies was measured. Depletions of antibodies were confirmed by ELISA.

ELISA confirmation of DENV2 or rEDIII-depleted sera. {#s3.11}
----------------------------------------------------

ELISA plates were coated directly with either 50 ng of DENV2 antigen or 100 ng DENV2 rEDIII per well at 4°C overnight. Plates were blocked as described above. Undepleted, control depleted, and antigen/rEDIII-depleted sera were diluted 1:40 in blocking buffer and were incubated on plates for 1 h at 37°C. DENV2 or rEDIII reactive antibodies were detected using the secondary antibody and substrate as described above.

SUPPLEMENTAL MATERIAL {#sm1}
=====================

###### 

DENV4 infectious clone. Reverse genetics system for manipulating DENV4 genome. DENV genome was divided into four plasmid cassettes that can be mutated individually, ligated together, and electroporated into cells to generate recombinant virus. The DENV4-A cassette contains the envelope gene; to highlight it, EDIII has been stippled. Replacement of EDIII residues with those from DENV2 in the DENV4 backbone creates the rDENV4/2 recombinant virus. A total of 58 nucleotide changes were introduced into the DENV4-A cassette (highlighted in red). Download

###### 

Figure S1, TIF file, 2.8 MB

###### 

Validation of recombinant virus purity. (A) Viruses were grown in C6/36 cells, and the culture supernatant was collected and centrifuged to remove any cellular debris. Viral RNA was isolated using the Qiagen QIAamp viral RNA Miniprep kit. Serotype-specific PCR was run for 35 cycles, and the PCR product was analyzed on a 1.5% Ultrapure agarose gel. Control RNA (DENV1, DENV2, DENV3, or DENV4) and water were run as positive or negative controls. The expected product sizes are as follows: DENV1, 205 bp; DENV2, 539 bp; DENV3, 455 bp; and DENV4, 401 bp. (B) Restriction fragment length polymorphism (RFLP) design to distinguish rDENV4/2 (bottom) from parental DENV4 (top). Mutations (represented as asterisks) introduced into DENV4 E gene to generate rDENV4/2 disrupted the XmnI enzyme restriction site present in DENV4. (C) PCR was used to amplify the E gene in both DENV4 and rDENV4/2. PCR products were gel purified and digested with XmnI. Digest products were analyzed on 1.5% Ultrapure agarose gel. The expected product sizes are as follows: full-length undigested, 1,031 bp; digested, 931 bp and 113 bp. Download
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###### 

rDENV4/2 neutralization by DENV2 and rEDIII depleted sera. A Vero-81 cell-based focus reduction neutralization test (FRNT) was performed using depleted DENV2 primary immune sera (A) and (B) depleted DENV2 vaccine sera (B). Solid circles, sera depleted using Dynabeads; solid triangles, sera depleted using polystyrene microspheres. Download
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Figure S3, TIF file, 2.8 MB
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Summary of amino acid changes in rDENV4/2 introducing a change of charge or polarity. Of 40 aa residues that were changed in recombinant virus, 14 introduced a change of charge. Six residues increase the negative charge (light red, from positive to uncharged; dark red, from uncharged to negative), while eight residues increase the positive charge (light blue, from negative to uncharged; dark blue, from uncharged to positive). Additional residue changes replace hydrophobic amino acids with polar amino acids and vice versa.
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Summary of MAbs used in this study.
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Summary of DENV immune sera used in this study.
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